
Viewpoint Molecular Targeting Announces Appointment of Markus Puhlmann as Chief Medical Officer



Dr. Puhlmann has over 20 years of oncology drug development experience and has spearheaded the global development and approval of multiple cancer drugs

Viewpoint Molecular Targeting, Inc, a radiopharmaceutical company developing precision lead-212-based α -particle oncology therapeutics and complementary diagnostic imaging agents announced the appointment of Markus Puhlmann, MD, MBA as Chief Medical Officer (CMO).

"Markus joins Viewpoint with an impressive track record of building and leading successful oncology programs," said Thijs Spoor, CEO of Viewpoint Molecular Targeting. "His broad, global experience across many tumor types at all stages of clinical development make him the ideal candidate to join Viewpoint as CMO. I am thrilled to have Markus on our management team and look forward to working together."

Dr Puhlmann has 20 years of experience in oncology drug development in solid and liquid tumor indications. Before joining Viewpoint, he was the CD30 Franchise Head of Global Clinical Development, Seagen. Prior to his time at Seagen, Dr. Puhlmann's work as Section Head at Merck & Co led to many successful regulatory filings for pembrolizumab in various indications for urothelial carcinoma, RCC and cervical cancer. Earlier in his career, he held various positions with increasing responsibilities in clinical development and medical affairs at Schering Plough, Bayer and Amgen. Dr. Puhlmann began his career as an academic physician in Germany, the UK and in the US at the National Cancer Institute (NCI).

Dr. Puhlmann commented, "The opportunity to lead the development of Viewpoint's pipeline programs is extremely exciting for me as a cancer drug developer. I think the application of targeted alpha-particle therapy will have a profound impact on the treatment of oncology patients."

Source: [Viewpoint Molecular Targeting](#)

Published on : Tue, 4 Oct 2022